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Table 1. Baseline patient characterisitcs
Patient Characteristics
TCD group
(n595)
Non-TCD
group (n555)
Sex: n (%)
Men 60 (63) 34 (62)
Women 35 (37) 21 (38)
Age: median (range) 50 (17-69) 48 (20-63)
Diagnosis: n (%)
Acute Leukemia/MDS 53 (56) 35 (64)
Non-Hodgkin Lymphoma 23 (24) 4 (7)
Chronic Leukemia 9 (9) 14 (25)
Others 10(11) 2 (4)
Conditioning regimen: n (%)
Myeloablative 69 (72.6) 45 (81.8)
Reduced intensity / non-myeloablative 26 (27.4) 10 (18.2)
Risk group: n (%)
Standard risk 13 (14) 21 (38)
High risk 82 (86) 34 (62)
Donor type: n (%)
Sibling 36 (37.9) 39 (70.9)
Unrelated 59 (62.1) 16 (29.1)
HLA mismatch: n (%) 13 (13.7%) 4 (7.3%)
CD 34+ dose: median (range) x
10*6/Kg body wt.
6.2 (1.9-16) 5.4 (1.2-12.9)
S310 Poster Session II(28.9% v 50%; p5 0.06), URD (48.3% v 64.7%; p5 0.23) andHLA
mismatched AHCT (p5 0.59), were not significantly different. The
incidence of chronic GVHD in the TCD and non-TCD groups was
41.1% (n 5 39) and 45.5% (n 5 25) respectively (p0.86). On sub-
group analysis of patients undergoing matched sibling, URD and
HLA-mismatched AHCT, no significant difference in rates of
cGVHD between the two groups was seen (p . 0.05). Relapse rates
in the TCD and non-TCD groups were 32.6% and 40% (p 5 0.22)
respectively. The overall survival at 3years was 39.2% in the TCD
group and 39.3% in the non-TCD group; p5 0.93. The 3year pro-
gression free survival in similar order were 34.8% and 27.2% respec-
tively (p5 0.85). Non relapse mortality at day 100 respectively were
12.8% and 16% and at 3years were 40% and 41% (p . 0.05).
Our limited, single institution experience in a cohort of 150 con-
secutive patients suggest no significant benefit with routine use of in
vivo TCD with AHCT. These results highlight the need to develop
novel strategies for preventing GVHD and for improving transplan-
tation outcomes.430
OUTCOMES FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION
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Human leukocyte antigen (HLA) identical sibling donor trans-
plantation remains the treatment of choice forWiskott Aldrich Syn-
drome (WAS), however, utilization of alternative donor sources has
significantly increased since 1990. We report the hematopoietic cell
transplantation (HCT) outcomes of 47 patients withWAS treated at
a single center since 1990 with significant improvement in outcomes
after 2000 despite the increased use of alternative donors. 5 year
overall survival (OS) improved from 62.5% (95% CI: 34.9% to
81.1%) to 90.8% (95% CI: 67.7% to 97.6%) for patients trans-
planted during 1990-2000 and 2001-2009, respectively. When
adjusted for age at HCT, OS was significantly higher in the 2001-
2009 era (p 5 0.04, Cox proportional hazard analysis). No early
transplant related mortality (within the first 100 days) occurred
among patients transplanted during 2001-2009 compared to 3/16
during 1990-2000, (p 5 0.03, Fisher’s exact test). The extent of
HLA mismatch did not significantly affect the incidence of acuteGVHD, chronic GVHD, or survival. Post-HCT autoimmune cyto-
penias were frequently diagnosed after 2001: 17/31 (55%) patients.
Their occurrence was not associated with transplant donor type
(p 5 0.53), or occurrence of acute GVHD (p 5 0.74), chronic
GVHD (p 5 0.12), or mixed chimerism (p 5 0.50).431
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Chronic active Epstein Barr virus infection (CAEBV) encom-
passes a variety of EBV-associated lymphoproliferative diseases
(LPD) in the non-immunocompromised host. In CAEBV either B,
T, and/or NK cells are primarily infected with EBV and patients
present with a variety of clinical signs and symptoms including fever,
hepatosplenomegaly, and lymphadenopathy. While rare in the
Western hemisphere, T and NK cell CAEBV is most commonly
seen in Japan. In Japan, current treatment protocols rely on chemo-
therapy and hematopoietic stem cell transplantation (HSCT).
To evaluate the clinical outcome of HSCT in CAEBV patients in
the United States, we reviewed our experience with 6 CAEBV pa-
tients (4 T-cell, 1 NK-cell, 1 B-cell), who underwent allogeneic
HSCT for their disease. Median age at transplant was 11 yrs (range
6 – 25 yrs) and the median time to transplant from diagnosis was 3.7
years (range 4.3 yrs – 8.5 yrs). Four of 6 patients had persistent or re-
fractory disease at the time ofHSCT. Four patients receivedmyeloa-
blative conditioning while 2 patients received reduced intensity
conditioning (RIC). Median time to neutrophil engraftment was
16 days (range days 11 – 21 days) with no long-term engraftment fail-
ure. Five patients received infusions of donor derived EBV-specific
cytotoxic T cells (CTLs) at a median of 6 months (range 2.5 months
– 12 months) post HSCT. Five patients are alive and in complete re-
mission with a median survival of 2.5 yrs (range 7 months – 10 yrs).
One patient developed recurrent T-cell CAEBV immediately post
transplant and died of an aggressive T-cell lymphoma 3.7 years
post transplant.
Our results support published data from Japan showing good out-
comes for CAEBV patients after allogeneic HSCT. Factors that may
influence outcome and warrant further study include the timing of
transplantation after diagnosis and the use of EBV-directed T-cell
therapies.432
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Allogeneic hematopoietic stem cell transplant (SCT) offers cura-
tive therapy to children with high-risk or relapsed acute lymphoblas-
tic leukemia (ALL). Here, we report encouraging results using
haploidentical related donor CD34+ selected (T-cell depleted) pe-
ripheral blood stem cell transplants in children with ALL in first
or second remission (CR1 or CR2). From May 2002 to September
2009, we transplanted 17 children (13 male, 4 female) in CR1 (n 5
6) and CR2 (n5 11) using primarily a fully myeloablative condition-
ing regimen consisting of cyclophosphamide 45mg/kg x 2 doses, cy-
tarabine arabinoside 3gm/m2 x 6 doses and total body irradiation
(TBI) 1400cGy (n5 12). Five patients received either a reduced-in-
tensity regimen or busulfan-based regimen for clinical purposes
(such as to avoid TBI exposure). All patients received alemtuzumab
(3, 5 or 10mg/dose depending on body weight) during conditioning
for in vivo T-cell depletion to promote engraftment and provide ad-
ditional GvHD protection. If the infused T-cell dose was less than
